Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ] - Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ] - Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ] - Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010
Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010

Curis to Present at the 9th Annual BIO Investor Forum


//health-fitness.news-articles.net/content/2010/ .. resent-at-the-9th-annual-bio-investor-forum.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the 9th Annual BIO Investor Forum at 10:00 a.m. Pacific time (1:00 p.m. EDT) on October 6, 2010, in San Francisco.

Dan Passeri, Curisa™ President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor that is being developed by Curisa™ collaborator Genentech. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting:

[ http://www.veracast.com/webcasts/bio/investorforum2010/63207481.cfm ]

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at [ www.curis.com ].


Publication Contributing Sources